Specialty Datasets Add Context to the Patient Journey
MapEnhance extends the value of our industry-leading Healthcare Map™ and provides the deepest and most complete view into the patient journey.
Now, you can select and access exclusive, highly-curated data sources — including lab, genomics, oncology Electronic Medical Record (EMR) data, race and ethnicity, social determinants of health (SDoH), mortality, and more — all carefully curated and refined by Komodo data scientists.
Obtain Real-World Data and Analytics
MapEnhance offers a fully integrated full-stack approach to obtaining real-world data and analytics. You can layer multiple datasets onto our comprehensive claims-based foundation via a single contract, and we deliver a pre-integrated, fit-for-purpose data product — so you can get the insights you need faster.
A BETTER WAY
The MapEnhance Advantage
Daily updates that provide the most up-to-date view of the market
Deep insight into the patient journey — provider-complete and payer-complete Mx claims, retail, specialty, PBM Rx claims
Connect the Healthcare Map to other sources using commonly used de-identified tokens
MapEnhance Gives You More
MapEnhance builds on our unmatched foundation to bring new depth to patient journeys and help answer questions previously out of reach.
KOMODO-BUILT DATA ENHANCEMENTS
Our high-fidelity specialty data products are rigorously de-duplicated, cleaned, formatted, and standardized by Komodo data scientists. Choose from datasets such as lab, clinical encounters, race and ethnicity, mortality data, and more.
KOMODO PARTNER DATA ENHANCEMENTS
Komodo also offers specialized and proprietary assets to enhance any patient cohort within the Healthcare Map.
Refine patient segmentation for targeted oncology treatment by integrating biomarker, demographic, and claims data.
Refine the patient cohort definition to assess brand utilization within the eligible lung cancer patient population over time.
Layer clinical and demographic data onto the non-Hodgkin's lymphoma population to characterize patients who aren't responding to first- and second-line therapies and might benefit from a new therapy clinical trial.
Enhance understanding of patient journeys across different races and ethnicities to inform clinical trial strategy and inclusion/exclusion criteria.
Enhance understanding of therapy effectiveness among specific disease populations to select more precise clinical endpoints.
Leverage detailed lab results and patient characteristics data to build a predictive model that will identify patients with a rare disease.
Perform a real-world evaluation of progression-free survival after initiation of an oncology drug.
Use specific biomarker data for precise patient identification and segmentation to support targeted treatment and assess the real-world differences in treatment rates and patterns.